

Date: March 28, 2019

To, The Manager, Listing Department, <b>National Stock Exchange of India Limited,</b> Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (E), Mumbai-400 051.	To, The Department of Corporate Service, <b>BSE Limited,</b> 1 <sup>st</sup> Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai-400 001.
<b>Scrip Code - LINCOLN</b>	<b>Scrip Code - 531633</b>

Dear Sir,

**Sub: Intimation under Regulation 30 of SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015.**

In accordance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, we would like to inform that:

1. The Board of Directors of the Company at their meeting held today (i.e. on March 28, 20149) have appointed Mr. Darshit Ashvinkumar Shah as a Chief Financial Officer [Key Managerial Personnel] of the Company with effect from March 28, 2019.

Mr. Darshit Ashvinkumar Shah is Chartered Accountant by profession and is having more than 10 years of experience in the field of Accounts and Finance. He is also having the experience of working in field of auditing, Fund Management and also has an experience of dealing in Direct and Indirect Taxation.

Considering his wide experience of working and academic background he has been appointed as Chief Financial Officer (Key Managerial Personnel) of the Company.

He is not a related of any members of the Board.

2. Appointment of M/s. Vishwas Sharma & Associates, Practicing Company Secretaries as Secretarial Auditor of the Company for the F.Y. 2018-19.

We request you to take the same on record.

Thanking you,

Yours faithfully,  
**FOR LINCOLN PHARMACEUTICALS LIMITED**

  
\_\_\_\_\_  
**MUNJAL M. PATEL**  
**WHOLE-TIME DIRECTOR**  
**DIN: 02319308**

